Planet TV Studios Airing “New Frontiers” Episode on NeOnc Technologies Holdings, Inc. – Saturday, April 12th, 2025 on Bloomberg. The content in the episode is a Planet TV Studios Original & it is brought to you by & sponsored by Planet TV Studios

April 12, 2025 02:57 AM AEST | By EIN Presswire
 Planet TV Studios Airing “New Frontiers” Episode on NeOnc Technologies Holdings, Inc. – Saturday, April 12th, 2025 on Bloomberg. The content in the episode is a Planet TV Studios Original & it is brought to you by & sponsored by Planet TV Studios
Image source: EIN Presswire

Planet TV Studios proudly serves as the exclusive sponsor of the New Frontiers series. NeOnc Technologies Holdings in New Frontiers Episode April 12th on Bloomberg Television.

WESTLAKE VILLAGE,, CA, UNITED STATES, April 11, 2025 /EINPresswire.com/ -- In an era when relentless innovation is the only answer to entrenched challenges, Planet TV Studios is re-running an incisive installment of its flagship series, New Frontiers. This fresh airing delves into the rigorous science and bold vision fueling NeOnc Technologies Holdings, Inc.—a company that is reimagining the approach to brain cancer through pioneering intranasal therapies. This renewed broadcast on Bloomberg Television is scheduled for Saturday, April 12, 2025, from 5:00 to 5:30 PM ET.

A Critical Examination of NeOnc’s Revolutionary Strategy
Under the stewardship of esteemed neurosurgeon Dr. Thomas Chen, NeOnc Technologies Holdings, Inc. is taking aim at one of modern medicine’s most formidable obstacles: the blood-brain barrier. Historically, this physiological barricade has imperiled traditional treatment modalities, stymieing progress against brain cancer. Now, NeOnc is challenging conventional wisdom with two experimental agents—NEO100 and NEO212.

NEO100 represents a highly purified form of perillyl alcohol.

NEO212 is an inventive fusion of temozolomide (TMZ) and perillyl alcohol.

Early clinical findings suggest that these compounds could signal a paradigm shift in the management of glioblastoma multiforme and metastatic brain tumors, offering potentially greater efficacy along with improved tolerability. “Brain cancer patients have long faced limited options, and our goal is to provide a meaningful alternative,” Dr. Chen asserts, underscoring the promise of an intranasal delivery mechanism specifically designed to circumvent the notorious blood-brain barrier.

Not content with just advancing treatment, NeOnc is also preparing for a significant evolution in its corporate journey—a direct listing on Nasdaq in the first quarter of 2025, a maneuver anticipated to broaden its research horizons and bolster its innovative pipeline.

Returning Expertise: Host Gina Grad
Bringing this narrative to life is returning host Gina Grad, whose journalistic rigor and knack for distilling complex medical science have become hallmarks of the series. Known for her incisive commentary—evident from her previous work on The Adam Carolla Show and her memorable contribution to children’s literature in My Extra Mom, a book about helping children cope with their blended families —Grad provides the contextual framework necessary to appreciate the broader implications of these medical breakthroughs. “I’m thrilled to be part of another season of New Frontiers,” she observes, reminding viewers that the journey of innovation is as much about the human spirit as it is about the science behind it.

How to Engage with the Innovation
For those poised to scrutinize the forefront of neurosurgical advancements, the re-airing of New Frontiers offers an in-depth look at the current trajectory of medical innovation. Tune into Bloomberg Television on Saturday, April 12, 2025, from 5:00 to 5:30 PM ET. Additionally, the episode will soon be available for on-demand streaming via platforms including Amazon, Vimeo, YouTube, Roku, Tumblr, X, Brighteon, Facebook, Rumble, Dailymotion, ReportWire, Newsbreak, and more—ensuring that this critical dialogue remains accessible to a national audience.

For More Information
For further insights into NeOnc Technologies Holdings, Inc., visit neonctech.com or email [email protected]. Additional details on New Frontiers and other initiatives from Planet TV Studios are available at planettvstudios.com, or by contacting Christian Alain at 888-210-4292 x100 or [email protected].

This re-airing is more than a mere repetition—it is a clarion call to a critical public discourse on the evolving landscape of medical innovation. In an age where breakthroughs must be as scrutinized as they are celebrated, New Frontiers challenges its viewers to weigh every development with the clarity and depth that our times demand.

Christian Kelch
Planet TV Studios
+1 888-210-4292 ext. 100
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
YouTube
Other

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.